Blinatumomab works by creating a bridge between T-cells and cancer cells. By binding to the CD19 protein on cancer cells and the CD3 protein on T-cells, it facilitates the immune system's ability to recognize and destroy cancer cells. This mechanism of action makes it highly effective in targeting specific cancer cells while minimizing damage to normal cells.
